160 related articles for article (PubMed ID: 36362213)
21. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
22. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
[TBL] [Abstract][Full Text] [Related]
23. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
24. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
25. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.
Marshall CH; Fu W; Wang H; Baras AS; Lotan TL; Antonarakis ES
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):59-65. PubMed ID: 30171229
[TBL] [Abstract][Full Text] [Related]
27. A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
Kosaka T; Hongo H; Aimono E; Matsumoto K; Hayashida T; Mikami S; Nishihara H; Oya M
Pathol Int; 2019 Dec; 69(12):715-720. PubMed ID: 31631483
[TBL] [Abstract][Full Text] [Related]
28. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
[TBL] [Abstract][Full Text] [Related]
29. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
31. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
[TBL] [Abstract][Full Text] [Related]
33. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
34. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
[TBL] [Abstract][Full Text] [Related]
35. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
36. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
37. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
[TBL] [Abstract][Full Text] [Related]
38. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
39. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva L; Lozano R; Llácer C; Aragón I; Pajares BI; Sáez MI; Herrera-Imbroda B; Montesa A; Hernández D; Villatoro R; Otero A; Correa R; Grau G; Peinado P; Pacheco MI; García-Galisteo E; Rueda A; Machuca FJ; Alba E; Márquez-Aragonés A; Olmos D; Castro E
Eur Urol Oncol; 2021 Apr; 4(2):315-318. PubMed ID: 31307957
[TBL] [Abstract][Full Text] [Related]
40. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
